Diaphragmatic Function as a Biomarker
Launched by RWTH AACHEN UNIVERSITY · Jun 5, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well the diaphragm, the main muscle used for breathing, works in people with respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and pulmonary hypertension. The researchers want to understand if problems with diaphragm function could explain why some patients experience shortness of breath, a common symptom in these conditions. By studying this, they hope to find a new way to assess and possibly predict how well patients with these lung diseases might do over time.
To participate in the trial, you need to be at least 18 years old and diagnosed with one of the lung diseases mentioned. You should also be able to understand the study and follow instructions. However, there are some reasons you might not be able to join, such as having a very high body mass index (BMI) or certain medical conditions. If you decide to participate, you can expect to undergo evaluations related to your diaphragm function, and your involvement could help improve understanding of breathing difficulties in lung disease patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patient has one of the following lung diseases: COPD, bronchial asthma, pulmonary fibrosis, pulmonary hypertension
- • is 18 years or older
- • is mentally and physically able to understand the study and to follow instructions
- • are legally competent
- • signed declaration of consent
- Exclusion Criteria:
- • BMI \> 35
- • current or treatments or diseases in the past which could influence the evaluation of the study
- • Expected lack of willingness to actively participate in study-related measures
- • alcohol or drug abuse
- • disc herniation/prolapse
- • epilepsy
- • wheelchair bound
- • in custody due to an official or court order
- • in a dependent relationship or employment relationship with investigating physician or one of their deputy
- • emergency inpatient hospital stay within 4 weeks before study-specific examinations
About Rwth Aachen University
RWTH Aachen University is a prestigious research institution located in Aachen, Germany, renowned for its commitment to advancing science and technology through innovative research and education. As a clinical trial sponsor, RWTH Aachen University leverages its interdisciplinary expertise and state-of-the-art facilities to conduct cutting-edge clinical research aimed at improving patient outcomes. The university collaborates with various healthcare stakeholders to facilitate the translation of scientific discoveries into effective therapeutic interventions, ensuring adherence to ethical standards and regulatory requirements throughout the research process. With a focus on fostering knowledge exchange and driving clinical advancements, RWTH Aachen University plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aachen, North Rhine Westphalia, Germany
Patients applied
Trial Officials
Michael Dreher, MD
Study Director
Uniklinik RWTH Aachen
Binaya Regmi, MD
Study Chair
Uniklinik RWTH Aachen
Jens Spiesshoefer, MD
Principal Investigator
Uniklinik RWTH Aachen
Mustafa Elfeturi
Study Chair
Uniklinik RWTH Aachen
Benedikt Jörn
Study Chair
Uniklinik RWTH Aachen
Faniry Ratsimba
Study Chair
Uniklinik RWTH Aachen
Felix Wagner
Study Chair
Uniklinik RWTH Aachen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported